CytoDyn Inc. Terminates Material Definitive Agreement
Ticker: CYDY · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1175680
| Field | Detail |
|---|---|
| Company | Cytodyn Inc. (CYDY) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $43,821,231.32, $250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-agreement, corporate-action
TL;DR
CytoDyn terminated a key deal, expect volatility.
AI Summary
CytoDyn Inc. announced on April 3, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware, is based in Vancouver, Washington, and operates in the Pharmaceutical Preparations sector.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction, financial obligations, and future operations.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's business relationships and financial stability.
Key Numbers
- 000-49908 — Commission File Number (SEC filing identifier for CytoDyn Inc.)
- 83-1887078 — I.R.S. Employer Identification No. (Tax identification number for CytoDyn Inc.)
Key Players & Entities
- CytoDyn Inc. (company) — Registrant
- April 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Vancouver, Washington (location) — Principal executive offices
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the exact nature or counterparty of the terminated material definitive agreement.
What is the effective date of the termination?
The earliest event reported is April 3, 2024, which is also the date of the report.
What are the potential financial implications of this termination for CytoDyn Inc.?
The filing does not detail the specific financial implications, but termination of material agreements typically carries financial consequences.
Was this termination a mutual decision or initiated by one party?
The filing states the termination of a material definitive agreement but does not specify who initiated it or if it was mutual.
Does this termination affect any ongoing clinical trials or product development for CytoDyn Inc.?
The filing does not provide information on whether this termination impacts ongoing clinical trials or product development.
Filing Stats: 815 words · 3 min read · ~3 pages · Grade level 14.9 · Accepted 2024-04-08 08:31:40
Key Financial Figures
- $43,821,231.32 — tructured under the Letter Agreement is $43,821,231.32. Except for a single $250,000 payment d
- $250,000 — is $43,821,231.32. Except for a single $250,000 payment due on or before December 31, 2
Filing Documents
- cydy-20240403x8k.htm (8-K) — 34KB
- 0001558370-24-004802.txt ( ) — 160KB
- cydy-20240403.xsd (EX-101.SCH) — 3KB
- cydy-20240403_lab.xml (EX-101.LAB) — 17KB
- cydy-20240403_pre.xml (EX-101.PRE) — 12KB
- cydy-20240403x8k_htm.xml (XML) — 4KB
02 Termination of Material Definitive Agreement
Item 1.02 Termination of Material Definitive Agreement. On April 3, 2024, CytoDyn Inc. (the "Company") and Samsung BioLogics Co., Ltd. ("Samsung") executed an agreement (the "Letter Agreement"), wherein the parties reached agreement for an orderly process for winding down services and a restructuring of the amount payable by the Company to Samsung (the "Total Balance"). The Letter Agreement resolves the Company's obligations under the Master Services Agreement and related ancillary agreements first entered into between Samsung and the Company in or around April 2019 (collectively, the "Agreement"). The Total Balance due as restructured under the Letter Agreement is $43,821,231.32. Except for a single $250,000 payment due on or before December 31, 2024, the entirety of the Total Balance is contingent, and will only be due and payable, upon the Company achieving a qualifying "Revenue" event, as defined in the Letter Agreement. Under the Letter Agreement, the Company agreed to pay 20% of its qualifying Revenue generated in each calendar year, if any, with such payments to be applied to reduce the Total Balance until it is repaid in full. Interest will not accrue on the Total Balance throughout the prospective repayment period. Revenue is defined in the Letter Agreement as: "the gross revenue generated by Client and its Affiliates, less the following items (if not previously deducted from the amount invoiced): (a) reasonable and customary trade, quantity, and cash discounts actually granted and legally permitted wholesaler chargebacks actually paid or credited by Client and its Affiliates to wholesalers of products; (b) reasonable, customary, and legally permitted rebates and retroactive price reductions actually granted; (c) freight charges for the delivery of products; (d) the portion of the administrative fees paid during the relevant time period to group purchasing organizations, pharmaceutical benefit managers and/or government-mandated Medicare or Medicaid P